Hookipa Pharma Files Petition to Validate Stockholder Actions at Annual Meetings

Hookipa Pharma Inc. recently filed a petition seeking validation for certain actions taken by the company’s stockholders at its 2022 and 2023 Annual Meetings. The petition, presented as a Section 205 Proceeding in the Delaware Court of Chancery, aims to address the fixing of record dates that deviated from the requirements of the Delaware General Corporation Law (DGCL).

The Section 205 Proceeding, titled In re Hookipa Pharma Inc., concerns actions approved at the 2022 Annual Meeting, which included electing two directors, amending the certificate of incorporation to increase authorized shares, and amending the 2019 Stock Option and Incentive Plan. Similarly, the 2023 Annual Meeting saw the approval of the election of three directors for three-year terms. These events prompted the company to seek validation under Section 205 of the DGCL.

Following approval from the Court of Chancery, a final hearing has been scheduled for February 14, 2025, to consider the petition’s merits. Stockholders have the opportunity to voice their positions either at the hearing or by submitting written statements to the Register in Chancery by email.

The Company’s legal counsel directed the Section 205 Proceeding for the validation of the stockholder actions taken at the Annual Meetings. The Court of Chancery approved an expedited motion, highlighting the importance of addressing the issues promptly.

The company’s filing also included details about the annual meetings, stockholder actions, record dates, and voting results. Hookipa Pharma emphasized its commitment to transparent corporate governance and adherence to legal regulations, underscoring the importance of validating the stockholder actions.

For further details about the legal proceedings and upcoming hearing, interested stakeholders are encouraged to review the official petition and related documents filed by Hookipa Pharma.

This comprehensive approach by Hookipa Pharma to address and regularize past stockholder actions showcases the company’s commitment to upholding corporate governance standards and ensuring transparency in their operations.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hookipa Pharma’s 8K filing here.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.